Lorlatinib in ALK- or ROS1-Positive Non-Small Cell Lung Cancer Patients: Experience from an Early Access Program in Turkey

Sezer, A.Ozyilkan, O.2020-10-202020-10-2020191556-0864https://www.jto.org/article/S1556-0864(19)31849-0/pdfhttp://hdl.handle.net/11727/4936enginfo:eu-repo/semantics/openAccessALK positiveROS1 positiveLorlatinibAdvanced stage lung cancerLorlatinib in ALK- or ROS1-Positive Non-Small Cell Lung Cancer Patients: Experience from an Early Access Program in TurkeyconferenceObject1410S558S559000492162203082